2.79
Schlusskurs vom Vortag:
$2.81
Offen:
$2.848
24-Stunden-Volumen:
14,687
Relative Volume:
0.81
Marktkapitalisierung:
$28.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.87M
KGV:
-0.1418
EPS:
-19.67
Netto-Cashflow:
$-47.63M
1W Leistung:
-2.11%
1M Leistung:
+2.95%
6M Leistung:
-21.30%
1J Leistung:
-40.06%
Polypid Ltd Stock (PYPD) Company Profile
Vergleichen Sie PYPD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PYPD
Polypid Ltd
|
2.79 | 29.04M | 0 | -23.87M | -47.63M | -19.67 |
![]()
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
2021-09-14 | Eingeleitet | JMP Securities | Mkt Outperform |
2021-07-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-11-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
2020-08-10 | Eingeleitet | Alliance Global Partners | Buy |
2020-07-21 | Eingeleitet | BMO Capital Markets | Outperform |
2020-07-21 | Eingeleitet | Barclays | Overweight |
2020-07-21 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Polypid Ltd Aktie (PYPD) Neueste Nachrichten
PolyPid chairman to step down at June shareholder meeting By Investing.com - Investing.com Nigeria
PolyPid chairman to step down at June shareholder meeting - Investing.com Australia
PolyPid Announces Leadership Changes Ahead of June 2025 Shareholder Meeting - TipRanks
PolyPid Opens Virtual Access to Investors: Key Presentation and 1-on-1 Meetings at Lytham Conference - Stock Titan
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 - GlobeNewswire
Head to Head Survey: PolyPid (NASDAQ:PYPD) & Lombard Medical (OTCMKTS:EVARF) - Defense World
Tenon Medical (NASDAQ:TNON) vs. PolyPid (NASDAQ:PYPD) Critical Comparison - Defense World
PolyPid Ltd. Earnings Call: Progress and Challenges - TipRanks
PolyPid Ltd. (NASDAQ:PYPD) Q1 2025 Earnings Call Transcript - Insider Monkey
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
PolyPid Ltd. Reports Q1 2025 Results and Trial Progress - TipRanks
Polypid Q1 Net Income USD -8.3 Million - marketscreener.com
PolyPid (PYPD) Prepares for Transformational 2025 with Promising - GuruFocus
PolyPid Completes Enrollment in Phase 3 Trial of D-PLEX100 - TipRanks
PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Transcript : PolyPid Ltd., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
PolyPid (PYPD) Expected to Announce Earnings on Wednesday - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update - Defense World
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 - GlobeNewswire
PolyPid Q1 2025 Earnings Preview: Surgical Outcomes Biopharma Reports May 14 - Stock Titan
Reviewing Baxter International (NYSE:BAX) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid to Participate in The Citizens Life Sciences Conference - GlobeNewswire
PolyPid to Reveal Next-Gen Surgical Innovation Pipeline at Elite Citizens Life Sciences Conference - Stock Titan
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Declines By 25.9% - Defense World
What is HC Wainwright’s Estimate for PolyPid Q1 Earnings? - Defense World
What is HC Wainwright’s Forecast for PolyPid Q1 Earnings? - Defense World
H.C. Wainwright maintains Buy on PolyPid stock with $11 target - Investing.com Australia
PolyPid’s (PYPD) Buy Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Buy on PolyPid stock with $11 target By Investing.com - Investing.com Canada
PolyPid stock touches 52-week low at $2.32 amid market challenges By Investing.com - Investing.com South Africa
PolyPid stock touches 52-week low at $2.32 amid market challenges - Investing.com Australia
Surgical Site Infections Clinical and Non-Clinical Studies, - openPR.com
Barclays Reaffirms Their Hold Rating on PolyPid (PYPD) - The Globe and Mail
Comparing Beta Bionics (NASDAQ:BBNX) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid Completes Enrollment in Phase 3 Trial for Surgical Infection Prevention - TipRanks
PolyPid Announces Successful Completion of Enrollment in - GlobeNewswire
PolyPid Announces Successful Completion Of Enrollment In Phase 3 Shield II Trial Of D-Plex100 For The Prevention Of Abdominal Colorectal Surgical Site Infections - Marketscreener.com
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - Yahoo
Critical Survey: Nyxoah (NASDAQ:NYXH) vs. PolyPid (NASDAQ:PYPD) - Defense World
PolyPid (NASDAQ:PYPD) Stock Price Up 0.7% – Should You Buy? - Defense World
PolyPid to Participate in the 37th Annual ROTH Conference - GlobeNewswire
PolyPid Fireside Chat at ROTH Conference: What New Surgical Innovations Will Management Reveal? - StockTitan
Polypid Ltd to Host Earnings Call - ACCESS Newswire
Finanzdaten der Polypid Ltd-Aktie (PYPD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):